PharmPK Discussion List Archive - 2010

PharmPK Discussion List Frequently Discussed Topics

A brand new NONMEM user
A question of clearance
AAPS Pharmaco-Imaging Roundtable
Abbreviations for maximum and minimum concentrations at steady state
Absorption rate constant
Accreditation for pharmacokinetic laboratories
Accuracy and precision limit for drug estimation in TPN
Add unit and axis label in WinNonlin v1.5
Allometric exponents
Allometry human to rat
Allometry: linear regression of log-transformed data or nonlinear fitting
Analysis of ELF-Plasma ratios
Analytical assay for topotecan
Analytical Method Validation - Linearity
Announcement: release of scaRabee, new R package for modeling and simulation
Antidrug antibody
Apparent volume of distribution in the mouse
Aqueous Solubility
Assay validation for tissue samples
AUC greater than 80% of AUC(inf)
AUCreftmax
Autoinduction factor for simulation
BA calculation
BA-BE Study in Rabbits
Bcrp over expressing cells request
BE study of dose weight proportionate formulations
BE study report validity
Betahistine 16mg BCS class I
Bioanalysis in formalin-fixed tissue
Bioanalytical method issues for bio-similar drugs
Bioavailability of oral drugs in hiatus hernia
Bioavailability study report for exam
Bioequivalence study for extended release formulations
Bioequivalence using a supra-therapeutic dose
Bioequivalence with changed manufacturing
Biomonitoring
Biorelevant Solubility Database
Biphasic Elimination
Blood flow values
Blood sampling time
Blood stability
Blood to plasma ratio
Blood vs tumor PK - non-parallel profiles
Book on PK PD
BQL set of rules
Break down of acetylated compound in plasma
Bronchial Alveolar Lavage Studies
Calculation of micro rate constants three compartment model
Calculation of t 1/2
Carbamazepine PgP induction
Carvedilol bioequivalence study
Cefditoren Bioavailability
Cerebral blood flow in rat
Choice of dosing intervals in repeated dose toxicity studies
Clavulanic acid absorption
Clearance and absorption
Clearance and bioavailability
Column Selection
Combination therapy
Compartmental pharmacokinetics
Concentration Dependent Absorption
Concentration of DMSO DMA in injectable solution
Confidence Intervals for Emax Model
Confirmatory re-assay
Correct for residual concentration
Cross validation between Rat plasma and Human Plasma
CSF Collection
Cumulative basolateral in caco-2
Cumulative Weibull expression
Cyclosporin sampling time
Cyclosporine assay method
CYP contribution
CYP normalisation data
DDI study designs
Determination of a drug in plasma and blood cellular fraction
Determination of IC50
Determination of Metabolic clearance
Difference in in vivo blood elimination half-life
Different formulation strength for oral and iv administration
Digits and decimals in concentrations reporting
Digoxin interaction sites
Disease modeling tool - PottersWheel 2.0 - released from TIKANIS
DMA and NMP in formulations
DMPK parameters in TPP
Dose adjustment of Cmax and AUC
Dose calculation and considerations for acute toxicity studies
Dose for acute toxicity studies
Dose Proportionality
Dose volume of IM injection
Drug analysis in plasma - hplc cleaning
Drug for IVIVC study
Drug levels in ELF from BAL
EC50 versus Cmax
EDTA or heparin
Effect of plasma protein binding on Metabolism
Effective half life
Elimination rate
EliSpot Assays
Endotoxin levels in NBE PK
Enhancement of solubility for enzyme kinetics
Enhancing t1/2 of an NCE
Enteric coated formulation
Entering PK parameter in Pharsight trial simulator
Enterohepatic reabsorption half-life
F greater than 1
Fexofenadine ODT: Study requirement
First dose in animals and humans
First in human dosing
Flip Flop modeling
Fluorescence based ion channel assay
Fluorescence sodium current
Force-feeding rat with capsule
Formulation affects on ADME
Formulation at pH 10 or higher
Four compartment model
Free and total fractions
Free fraction in blood
Full versus partial validation
Gender specificity in beagle dogs
GLP certification for BA-BE studies
Glucosamine from human plasma
Graphing with R
Half life calculation-first order-noncompartmental analysis
Hemolysed blood sample
Hepatic blood flow in each species
How to calculate Km
How to choose animal model for PK study
How to determine dose linearity
How to determine outliers on a PK curve
How to perform PK for two time point conc
How to skip "Missing" values when calling DTA() function in WinNonlin
How to validate MPA equation
HPLC column cleaning
HPLC method of ranolazine hydrochloride
HPLC system
HPLC using microbore columns
Human efficacious dose
Hydration on small Vss
Implications of drug reactivity with formaldehyde
In vitro half life much more than in vivo
in vivo Glucuronide conjugation inhibitors
In-Vitro drug profiling
In-vitro Microsomal stability - non-P450 turnover data
Increased volume of distribution with age
Infusion to steady state
Input and interpretation deconvolution results
Internal standard variation
Interpret volume of distribution
Intrinsic clearance of 7-hydroxycoumarin
Ion suppression quantification
Is Simcyp able to include tissue drug specific target binding for Vss calculation
Isobologram software
IV vehicle in rat PK study
Ketoconazole inhibition potential
Ki on CYP2C9 in rat mice
LC peak splitting
LcMsMs system for medical drug screening
Learning of pharmacokinetics
Less than LOQ data in PK modeling
Linearity in the new EMA guideline
Liver extraction ratio
Liver microsome stability assay
Log PA classification
Low bioavailability
Low bioavailability drugs list
Lymph volume and lymph flow rate
Macrogol 15 hydroxystearate
Mass selection
Mass Spec Calibration
Matrix effect
Mean dissolution time
Metabolite clearance
Method development of Sildenafil
Method development problems
MIC calculation
Microsomal t1/2 of Verapamil and Piroxicam
Modeling approach
Monkey transporters
MS mz value
Multi-compartment model
Multiple dose BE study-fasting or fed
Naive question on ke and t1/2
Nano-loaded formulation of anti-HIV drugs
Nanoformulation and its pharmacokinetic evaluation
Nanosizing effect
Nominal percent
Non linear bioavailabilty
Non-specific binding in transporter assays
Noncompartment analysis with NONMEM
NONMEM Data Set
NONMEM perl script
Olanzapine
Olmesartan Bioavailability
Omeprazole metabolite(s) request
One compartment zero order absorption
Open access combination therapy database launched
Outliers in bioequivalence studies
Passage Number Effects In Caco-2 Cell Line
Percent CV in NHP and Humans
Permeability assay cell lines
Permeability assay using caco-2 cell line
PFS vs. Vial BE
pH solubility assay of an oily compound
Pharmacokinetic parameters for a metabolite
Pharmacokinetics of Donepezil in the Rat
PHARMAPENDIUM(TM) Launches Pharmacokinetics Module
Pharmasolve in oral formulations
Phase V clinical trial
Phoenix Threshold for RSQ
Phosphate ester hydrolysis
PK analysis within Watson LIMS
PK criteria to continue drug development
PK of oral drugs in gastric cancer patients
PK-PD modeling
PKPD modeling of collagen-induced arthritis in mice
Placebo effect
Plasma of Different population
Plasma protein binding was calculated to be negative
PLT Tools version 3.0
Poor bioavailability opthalmic drugs
POP_PHARM in Israel
POPPK study for Atorvastatin
Population bioequivalence.
Population PK and NONMEM
Protein - P450 drug interactions
Protein Binding
QC acceptance criteria - %CV
QC accuracy 4-6-30 rule
Quantitation of TK samples based on dosing solution
Questionnaire Interspecies website
Rapid plasma protein binding assay
RED Device Human plasma variation
Reference dose for BE study
Reference product list
Reference scaled biostudies
Reference-Scaled Approach - FDA
Reg BacTiter-Glo Assay
Rejection of hemolyzed sample for bio analysis
Retention time of N-Oxyde metabolite
Rounding rule used in WNL
Rounding rules
Running R after a Nonmem run
S9 in drug metabolism study
Sample size for a parallel study
Sample size for BE study
Significance of Slopes in a GLP, non GLP setup
Simulation of human clearance using montecarlo in excel
Simultaneous estimation of Vitamin B12, B6... LC-MS
Sirolimus BCS
Smooth in bioanalysis
Snapshot PK
Solubility problem
Solution to a differential equation for a PD model
Solvents for sample preparation for LC-MS analysis
Species differences in GI tract and impact on oral %F
Stability of analyte in blood
Stability profiles
Stability Validation
Standard error of adjusted treatment means
Stanpump and preparing graphs
Steroid estimation
Steroid method development
Studying capsule formulations in mice
Supersaturated SEDDS and oily compounds
Survey: Value of collecting PK data in late phase clinical trials
Survey: What is Cmin
Systemic availability after inhalation
Systemic Availability vs Absolute Bioavailability
T1/2 and MRT relationship
Target Mediated Drug Disposition
Terizidone
Theophylline Clearance in CHF
Therapeutic drug targets database
Three way BE study
Tinn-R Settings
Toxicity for Bioequivalent
Transdermal Bioequivalence
Triptorelin assay in plasma
UPLC extraction problem
Use of anticoagulants with counter ions
Validation of Bioanalytical Method
Vancomycin dosing and monitoring
Variation in buprenorphine Cmax and AUC
Vehicle for nanosphere formulation
Vehicle formulation for dogs
Vehicle selection for lipophilic diterpenoids
Vitamin estimation in human plasma
Vitamin K2 BA, BE studies
Volume of distribution
Volume of Distribution and Clearance
Weighted curve fitting with Berkeley Madonna
Weighting PK data
Whole blood stability of drug
Wild type MDCK and MDR1-MDCK
WinNonlin Rsq, Rsq_adjusted and Correlation Coefficient
WinNonlin user defined model
WinNonlin with TID dosing

Visit the PharmPK Website for more information